Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) rose 3.8% on Monday after Bank of America raised their price target on the stock from $23.00 to $25.00. Bank of America currently has a buy rating on the stock. Hims & Hers Health traded as high as $23.06 and last traded at $22.99. Approximately 3,436,408 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 8,182,007 shares. The stock had previously closed at $22.15.
Other equities research analysts have also recently issued reports about the stock. Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a report on Wednesday, August 7th. Piper Sandler reissued a “neutral” rating and set a $18.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Jefferies Financial Group increased their price objective on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, June 27th. Finally, Needham & Company LLC began coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective on the stock. Eight research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $20.21.
Read Our Latest Report on Hims & Hers Health
Insiders Place Their Bets
Institutional Investors Weigh In On Hims & Hers Health
A number of institutional investors have recently made changes to their positions in HIMS. Vanguard Group Inc. raised its position in shares of Hims & Hers Health by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 14,173,285 shares of the company’s stock worth $126,142,000 after acquiring an additional 46,541 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in Hims & Hers Health during the 4th quarter worth approximately $155,000. Los Angeles Capital Management LLC grew its position in Hims & Hers Health by 58.5% in the 1st quarter. Los Angeles Capital Management LLC now owns 28,206 shares of the company’s stock valued at $436,000 after purchasing an additional 10,405 shares during the period. Counterpoint Mutual Funds LLC acquired a new stake in shares of Hims & Hers Health in the 1st quarter worth about $285,000. Finally, State of Michigan Retirement System purchased a new position in shares of Hims & Hers Health during the first quarter valued at approximately $2,785,000. Institutional investors own 63.52% of the company’s stock.
Hims & Hers Health Price Performance
The company has a market cap of $4.94 billion, a PE ratio of 276.91 and a beta of 1.06. The company’s fifty day moving average price is $16.94 and its 200 day moving average price is $17.61.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. The business had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. Hims & Hers Health’s revenue was up 51.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.03) earnings per share. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.
Hims & Hers Health Company Profile
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
See Also
- Five stocks we like better than Hims & Hers Health
- P/E Ratio Calculation: How to Assess Stocks
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Stock Splits, Do They Really Impact Investors?
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.